edoc

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma : 10 years of follow-up of the GHSG HD9 study

Engert, Andreas and Diehl, Volker and Franklin, Jeremy and Lohri, Andreas and Dörken, Bernd and Ludwig, Wolf-Dieter and Koch, Peter and Hänel, Mathias and Pfreundschuh, Michael and Wilhelm, Martin and Trümper, Lorenz and Aulitzky, Walter-Erich and Bentz, Martin and Rummel, Mathias and Sezer, Orhan and Müller-Hermelink, Hans-Konrad and Hasenclever, Dirk and Löffler, Markus. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma : 10 years of follow-up of the GHSG HD9 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27. pp. 4548-4554.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6005058

Downloads: Statistics Overview

Abstract

PURPOSE: The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) chemotherapy regimen in 1,196 patients with advanced-stage Hodgkin's lymphoma (HL). The previous analysis with 5 years median follow-up had indicated improved tumor control with BEACOPP escalated. Since the long-term safety and efficacy of this regimen has been debated, we report the 10-year follow-up. PATIENTS AND METHODS: Patients received one of three chemotherapy regimens: eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); eight cycles of BEACOPP baseline; or eight cycles of BEACOPP escalated. RESULTS: Median follow-up was 111 months. At 10 years, freedom from treatment failure (FFTF) was 64%, 70%, and 82% with OS rates of 75%, 80%, and 86% for patients treated with COPP/ABVD (arm A), BEACOPP baseline (arm B), and BEACOPP escalated (arm C), respectively (P > .001). BEACOPP escalated was significantly better than BEACOPP baseline in terms of FFTF (P > .0001) and OS (P = .0053). A total of 74 second malignancies (6.2%) were documented, including acute myeloid leukemia (0.4%, 1.5%, and 3.0%), non-Hodgkin's lymphoma (2.7%, 1.7%, and 1.0%), and solid tumors (2.7%, 3.4%, and 1.9%). The corresponding overall secondary malignancy rates were 5.7%, 6.6%, and 6.0%, respectively. CONCLUSION: The 10-year follow-up of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced-stage HL. These results challenge ABVD as standard of care for this patient population.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Allgemeine innere Medizin Liestal (Zimmerli)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Allgemeine innere Medizin Liestal (Zimmerli)
UniBasel Contributors:Lohri, Andreas N.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:American Society of Clinical Oncology
ISSN:0732-183X
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:24 May 2013 09:22
Deposited On:24 May 2013 09:04

Repository Staff Only: item control page